| These headings link you to the corresponding sections below |
Click  Show Links to expand a section or sub-section |
|
  |
|
Clinic Resources and Tools |
|
|
|
 |
 |
Vaccine schedules |
|
|
Vaccine administration |
|
|
Clinical considerations for use
of COVID-19 vaccines |
|
|
Clinical care considerations |
|
|
Vaccine safety |
|
|
Vaccine storage and handling (includes temperature logs) |
|
|
Training materials for providers |
|
|
Administrative and operational
issues |
|
 |
|
Information about COVID-19 Vaccine Products |
|
|
|
|
|
|
|
|
|
|
|
Pfizer-BioNTech COVID-19 vaccine (mRNA)
 All formulations
Note: All remaining doses of Pfizer-BioNTech's purple cap formulation expire on September 30, 2022. Information related to this formulation has been removed from this webpage.
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Moderna COVID-19 vaccine (mRNA)
 All formulations
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
|
Novavax COVID-19 Vaccine, Adjuvanted (protein subunit)
Show Links |
|
|
|
|
|
|
|
|
Janssen COVID-19 Vaccine (Johnson & Johnson) (viral vector)
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
Vaccine Fact Sheets (EUA, FDA-Licensed, and EUI) |
|
|
Fact Sheets for Pfizer-BioNTech COVID-19 Vaccines
 Age 6 months through 4 years (maroon cap) [monovalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
 Age 5 through 11 years (orange cap) [monovalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Age 12 years and older – do not dilute (gray cap)
[monovalent and bivalent formulations]
Show Links |
|
|
|
|
|
|
Monovalent (primary series only) |
|
|
|
|
|
|
|
|
|
|
|
|
– Emergency Use Instructions (EUI) |
|
|
|
|
|
|
|
|
|
Bivalent (booster only) |
|
|
|
|
|
|
|
|
Fact Sheets for Moderna COVID-19 Vaccines
 Age 6 months through 5 years (dark blue cap, magenta [pink] border)
[monovalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
 Age 6 through 11 years (dark blue cap, purple border) [monovalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
|
 Age 12+ years (red cap, light blue border) [monovalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Emergency Use Instructions (EUI) |
|
|
|
|
|
|
 Age 18+ years for booster (blue cap, gray border) [bivalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
Fact Sheets for Novavax COVID-19 Vaccine, Adjuvanted
 Age 12+ years (royal blue cap) [monovalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
Fact Sheets for Janssen (Johnson & Johnson) COVID-19 Vaccine
 Age 18+ years (blue cap) [monovalent]
Show Links |
|
|
|
|
|
|
|
|
|
|
|
|
|
COVID-19 Vaccine Emergency Use Instructions (EUI) Resources (CDC)
Show Links |
|
|
|
|
|
|
|
| Clinic Resources and Tools |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| General vaccine administration information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pfizer-BioNTech COVID-19 vaccine (mRNA)
All formulations |
|
|
|
|
|
|
|
| Age 6 months through 4 years (maroon cap) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
| Age 5 through 11 years (orange cap) [monovalent] |
|
|
|
|
|
|
|
|
|
|
Age 12 years and older – do not dilute (gray cap)
[monovalent and bivalent formulations] |
|
|
|
|
|
|
|
|
|
|
Moderna COVID-19 vaccine (mRNA)
Age 6 months through 5 years (dark blue cap, magenta [pink] border)
[monvalent] |
|
|
|
|
|
|
|
|
|
|
| Age 6 through 11 years (dark blue cap, purple border) [monovalent] |
|
|
|
|
|
|
Vaccine Preparation and Administration Summary: Moderna (n/a) |
|
|
|
|
|
|
|
| Age 12+ years (red cap, light blue border) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Age 18+ years for booster (blue cap, gray border) [bivalent] |
|
|
|
|
|
|
|
| Novavax COVID-19 Vaccine, Adjuvanted (protein subunit)
Age 12+ years (royal blue cap) [monovalent] |
|
|
|
|
|
|
|
|
| Janssen COVID-19 Vaccine (Johnson & Johnson) (viral vector)
Age 18+ years (blue cap) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical considerations for use of COVID-19 vaccines
Show Links |
|
|
|
|
|
|
|
|
|
COVID-19 Vaccines, Recommendations, and Schedules |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Safety |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Special Situations and Populations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Appendices |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Severe Allergic Reactions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccine storage and handling (includes temperature logs)
Show Links |
|
|
|
|
| General storage and handling information |
|
|
|
|
|
|
|
|
|
|
|
|
COVID-19 Vaccine Storage Temperature Logs |
|
|
 |
|
Ultra-Cold Freezer (Pfizer-BioNTech vaccine) |
|
|
|
|
|
|
|
|
|
|
Freezer (Moderna vaccine) |
|
|
|
|
|
|
|
|
|
|
Refrigerator (Pfizer-BioNTech, Moderna, Novavax, and Janssen vaccines) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pfizer-BioNTech COVID-19 vaccine (mRNA)
All formulations |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Age 6 months through 4 years (maroon cap) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Age 5 through 11 years (orange cap) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Age 12 years and older – do not dilute (gray cap)
[monovalent and bivalent formulations] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Moderna COVID-19 vaccine (mRNA)
All formulations |
|
|
|
|
|
|
|
Age 6 months through 5 years (dark blue cap, magenta [pink] border)
[monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Age 6 through 11 years (dark blue cap, purple border) [monovalent] |
|
|
|
|
|
|
|
|
|
Beyond-Use Date (BUD) Tracking Labels for Vaccine During Freezer or Refrigerator Storage: Moderna (n/a) |
|
|
| Age 12+ years (red cap, light blue border) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Age 18+ years (blue cap, gray border) [bivalent] |
|
|
|
|
| Note: Storage and handling of the Moderna bivalent formulation is identical to the monovalent formulations shown above. The bivalent product will be added to CDC's Storage and Handling Summary during future updates. |
|
| Novavax COVID-19 Vaccine, Adjuvanted (protein subunit)
Age 12+ years (royal blue cap) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
Janssen COVID-19 Vaccine (Johnson & Johnson) (viral vector)
Age 18+ years (blue cap) [monovalent] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccine Provider Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Considerations for Vaccination of Special Populations |
|
|
|
|
|
|
|
|
|
Reimbursement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACIP Recommendations
Vaccine Information Statements 
